What Happened

The FDA granted 510(k) clearance to Click Therapeutics' Motivista, a prescription digital therapeutic (PDT) delivered via smartphone, for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care in adults with stable positive symptoms. This is the first FDA-authorized treatment indicated specifically for negative symptoms of schizophrenia in the United States.

The clearance was supported by the Phase 3 CONVOKE study, which showed a 6.8-point improvement in negative symptom severity (CAINS-MAP) at 16 weeks versus 4.2 points in the digital control arm — a 62% relative improvement (Cohen's d -0.36; P=0.0003). Results were published in JAMA Network Open.

Who Is Affected

Click Therapeutics is the primary beneficiary, now holding the first FDA-authorized digital therapeutic for negative schizophrenia symptoms. Patients aged 18+ with schizophrenia and stable positive symptoms are the target population. The company's CCO Richard DeNunzio explicitly referenced payer and state Medicaid programs as key coverage targets, indicating that commercial launch and reimbursement efforts are underway.

Market Impact

• Creates a new category in digital therapeutics for schizophrenia, opening market access and payer negotiation opportunities.
• High sustained app usage (70.4% through week 15) and ~1 hour/week engagement comparable to in-person therapy strengthen value proposition for payers.
• No serious treatment-related adverse events reported, supporting safety profile for formulary inclusion.
• B2B vendors in commercialization, real-world evidence, patient engagement, and payer strategy have a clear trigger to engage Click Therapeutics as it scales.

What to Watch

Click is conducting an open-label extension study to deliver additional data on engagement and durability of effect. Watch for payer coverage decisions, particularly from state Medicaid programs, and any partnership or business development announcements as the company commercializes Motivista. The Phase 3 data publication in JAMA Network Open adds credibility for future partnership outreach.

Related coverage

• Click Therapeutics wins FDA clearance for Motivista, first digital therapeutic for schizophrenia negative symptoms
• FDA approves AbbVie's Parkinson's drug Juvmo (tavapadon) developed from UVA research
• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• Mirum Pharmaceuticals Wins FDA Approval for Atebrioz for Rare Bone Disorder FOP